Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Fukuya A, Okamoto K, Miyamoto H, Muguruma N, Fujikawa K, Takahashi Y, Takayama T. Sagawa T, et al. Among authors: miyamoto h. Sci Rep. 2020 Nov 13;10(1):19815. doi: 10.1038/s41598-020-76756-1. Sci Rep. 2020. PMID: 33188279 Free PMC article.
Colorectal xanthomas with polypoid lesion: report of 25 cases.
Nakasono M, Hirokawa M, Muguruma N, Okahisa T, Okamura S, Ito S, Miyamoto H, Wada S, Fukuda T, Sano T. Nakasono M, et al. Among authors: miyamoto h. APMIS. 2004 Jan;112(1):3-10. doi: 10.1111/j.1600-0463.2004.apm1120102.x. APMIS. 2004. PMID: 14961968 Review.
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J. Hirakawa M, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22. Cancer Chemother Pharmacol. 2013. PMID: 23338051 Clinical Trial.
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T. Tomonari T, et al. Among authors: miyamoto h. Oncotarget. 2016 Feb 9;7(6):7207-15. doi: 10.18632/oncotarget.6889. Oncotarget. 2016. PMID: 26769852 Free PMC article.
Localized amyloidosis of the stomach mimicking a superficial gastric cancer.
Kagawa M, Fujino Y, Muguruma N, Murayama N, Okamoto K, Kitamura S, Kimura T, Kishi K, Miyamoto H, Uehara H, Takayama T. Kagawa M, et al. Among authors: miyamoto h. Clin J Gastroenterol. 2016 Jun;9(3):109-13. doi: 10.1007/s12328-016-0651-x. Epub 2016 May 12. Clin J Gastroenterol. 2016. PMID: 27170299 Review.
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T, Kimura T, Shimoyama R, Kawamoto S, Sakamoto K, Goda F, Miyamoto H, Negoro Y, Tsuji A, Yoshizaki K, Goji T, Kitamura S, Yano H, Okamoto K, Kimura M, Okahisa T, Muguruma N, Niitsu Y, Takayama T. Takaoka T, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2016 Aug;78(2):397-403. doi: 10.1007/s00280-016-3096-5. Epub 2016 Jun 24. Cancer Chemother Pharmacol. 2016. PMID: 27342247 Clinical Trial.
Influence of metabolic syndrome on upper gastrointestinal disease.
Sogabe M, Okahisa T, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T. Sogabe M, et al. Among authors: miyamoto h. Clin J Gastroenterol. 2016 Aug;9(4):191-202. doi: 10.1007/s12328-016-0668-1. Epub 2016 Jul 2. Clin J Gastroenterol. 2016. PMID: 27372302 Review.
1,921 results